Abstract
Background/Aims: Sclerostin, osteoprotegerin, and bone-specific alkaline phosphatase (B-ALP), which are primarily related to bone metabolism, have been linked with insulin resistance in adults. We aimed to evaluate the association of these markers with growth, obesity, and parameters of insulin resistance in lean and obese children and adolescents. Methods: We measured sclerostin, osteoprotegerin, and B-ALP in fasting and oral glucose tolerance test (oGTT) serum samples from 1,325 children and adolescents, and during 24-h profiles and after exercise and glucose exposure in young adults. Results: In addition to the positive relationship with height standard deviation scores (SDS), sclerostin (r = 0.035, p < 0.001) and B-ALP (r = 0.06, p = 0.028) increased, whereas osteoprotegerin (r = –0.098, p < 0.001) decreased with BMI SDS. Furthermore, B-ALP correlated with fasting- and oGTT-derived markers of glucose and insulin metabolism suggestive of insulin resistance. To evaluate potential confounding diurnal variation of bone markers, we performed 24-h profiles. B-ALP and osteoprotegerin had lower night-time levels. Exercise acutely and transiently increased B-ALP and osteoprotegerin levels, but glucose ingestion had no effect. Conclusions: Besides their association with growth, sclerostin and osteoprotegerin levels are altered in childhood obesity. Particularly B-ALP was related to insulin resistance indices. Our findings accent the link between bone, growth, and insulin resistance.
References
1.
Kiess
W
, Penke
M
, Sergeyev
E
, Neef
M
, Adler
M
, Gausche
R
, et al. Childhood obesity at the crossroads
. J Pediatr Endocrinol Metab
. 2015
May
;28
(5-6
):481
–4
.
[PubMed]
0334-018X2.
Landgraf
K
, Friebe
D
, Ullrich
T
, Kratzsch
J
, Dittrich
K
, Herberth
G
, et al. Chemerin as a mediator between obesity and vascular inflammation in children
. J Clin Endocrinol Metab
. 2012
Apr
;97
(4
):E556
–64
.
[PubMed]
0021-972X3.
Flemming
GM
, Petzold
S
, Meigen
C
, Körner
A
, Kiess
W
, Kratzsch
J
. Is circulating osteocalcin related to adipokines and overweight/obesity in children and adolescents?
Exp Clin Endocrinol Diabetes
. 2012
Jul
;120
(7
):383
–7
.
[PubMed]
0947-73494.
Daniele
G
, Winnier
D
, Mari
A
, Bruder
J
, Fourcaudot
M
, Pengou
Z
, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism
. Diabetes Care
. 2015
Aug
;38
(8
):1509
–17
.
[PubMed]
0149-59925.
Delgado-Calle
J
, Sato
AY
, Bellido
T
. Role and mechanism of action of sclerostin in bone
. Bone
. 2017
Mar
;96
:29
–37
.
[PubMed]
8756-32826.
Fischer
DC
, Mischek
A
, Wolf
S
, Rahn
A
, Salweski
B
, Kundt
G
, et al. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase
. Ann Clin Biochem
. 2012
Nov
;49
(Pt 6
):546
–53
.
[PubMed]
0004-56327.
Canalis
E
. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
. Nat Rev Endocrinol
. 2013
Oct
;9
(10
):575
–83
.
[PubMed]
1759-50298.
Singh
R
, De Aguiar
RB
, Naik
S
, Mani
S
, Ostadsharif
K
, Wencker
D
, et al. LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans
. Cell Metab
. 2013
Feb
;17
(2
):197
–209
.
[PubMed]
1550-41319.
Morena
M
, Jaussent
I
, Dupuy
AM
, Bargnoux
AS
, Kuster
N
, Chenine
L
, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications
. Nephrol Dial Transplant
. 2015
Aug
;30
(8
):1345
–56
.
[PubMed]
0931-050910.
Wasilewska
A
, Rybi-Szuminska
AA
, Zoch-Zwierz
W
. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents
. J Pediatr Endocrinol Metab
. 2009
Dec
;22
(12
):1099
–104
.
[PubMed]
0334-018X11.
Monseu
M
, Dubois
S
, Boursier
J
, Aubé
C
, Gagnadoux
F
, Lefthériotis
G
, et al. Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults
. Diabetes Metab
. 2016
Nov
;42
(5
):364
–7
.
[PubMed]
1262-363612.
Niu
Y
, Yang
Z
, Li
X
, Zhang
W
, Lu
S
, Zhang
H
, et al. Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study
. BMC Endocr Disord
. 2015
Dec
;15
(1
):75
.
[PubMed]
1472-682313.
Suliburska
J
, Bogdanski
P
, Gajewska
E
, Kalmus
G
, Sobieska
M
, Samborski
W
. The association of insulin resistance with serum osteoprotegerin in obese adolescents
. J Physiol Biochem
. 2013
Dec
;69
(4
):847
–53
.
[PubMed]
1138-754814.
Erol
M
, Bostan Gayret
O
, Tekin Nacaroglu
H
, Yigit
O
, Zengi
O
, Salih Akkurt
M
, et al. Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children
. Iran Red Crescent Med J
. 2016
Nov
;18
(11
):e41873
.
[PubMed]
2074-180415.
Kotanidou
EP
, Kotanidis
CP
, Giza
S
, Serbis
A
, Tsinopoulou
VR
, Karalazou
P
, et al. Osteoprotegerin increases parallel to insulin resistance in obese adolescents
. Endocr Res
. 2018
Jun
;•••
:1
–7
.
[PubMed]
0743-580016.
Joslowski
G
, Goletzke
J
, Cheng
G
, Günther
AL
, Bao
J
, Brand-Miller
JC
, et al. Prospective associations of dietary insulin demand, glycemic index, and glycemic load during puberty with body composition in young adulthood
. Int J Obes
. 2012
Nov
;36
(11
):1463
–71
.
[PubMed]
0307-056517.
Rauchenzauner
M
, Schmid
A
, Heinz-Erian
P
, Kapelari
K
, Falkensammer
G
, Griesmacher
A
, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years
. J Clin Endocrinol Metab
. 2007
Feb
;92
(2
):443
–9
.
[PubMed]
0021-972X18.
Ali
AT
, Paiker
JE
, Crowther
NJ
. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin
. Am J Clin Pathol
. 2006
Sep
;126
(3
):437
–42
.
[PubMed]
0002-917319.
Cheung
CL
, Tan
KC
, Lam
KS
, Cheung
BM
. The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: a structural equation modeling approach
. J Clin Endocrinol Metab
. 2013
Sep
;98
(9
):3856
–63
.
[PubMed]
0021-972X20.
Poulain
T
, Baber
R
, Vogel
M
, Pietzner
D
, Kirsten
T
, Jurkutat
A
, et al.; LIFE Child study team
. The LIFE Child study: a population-based perinatal and pediatric cohort in Germany
. Eur J Epidemiol
. 2017
Feb
;32
(2
):145
–58
.
[PubMed]
0393-299021.
Löffler
D
, Müller
U
, Scheuermann
K
, Friebe
D
, Gesing
J
, Bielitz
J
, et al. Serum irisin levels are regulated by acute strenuous exercise
. J Clin Endocrinol Metab
. 2015
Apr
;100
(4
):1289
–99
.
[PubMed]
0021-972X22.
Kromeyer-Hauschild
K
, Wabitsch
M
, Kunze
D
, Geller
D
, Geiss
HC
, Hesse
V
, et al. Percentiles of body mass index in children and adolescents evaluated from different regional German studies
. Monatsschr Kinderheilkd
. 2001
;149
(8
):807
–18
. 0026-929823.
National High Blood Pressure Education Program Working Group on High Blood Pressure in C
,Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004
: 114(2 Suppl 4th Report): 555-76.24.
Friedrich
N
, Wolthers
OD
, Arafat
AM
, Emeny
RT
, Spranger
J
, Roswall
J
, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays
. J Clin Endocrinol Metab
. 2014
May
;99
(5
):1675
–86
.
[PubMed]
0021-972X25.
Alberti
KG
, Zimmet
PZ
. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
. Diabet Med
. 1998
Jul
;15
(7
):539
–53
.
[PubMed]
0742-307126.
Geistanger
A
, Arends
S
, Berding
C
, Hoshino
T
, Jeppsson
JO
, Little
R
, et al.; IFCC Working Group on Standardization of Hemoglobin A1c
. Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden
. Clin Chem
. 2008
Aug
;54
(8
):1379
–85
.
[PubMed]
0009-914727.
Dimitri
P
, Wales
JK
, Bishop
N
. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass
. Bone
. 2011
Feb
;48
(2
):189
–96
.
[PubMed]
8756-328228.
Kang
JH
. Association of Serum Osteocalcin with Insulin Resistance and Coronary Atherosclerosis
. J Bone Metab
. 2016
Nov
;23
(4
):183
–90
.
[PubMed]
2287-637529.
Tobiume
H
, Kanzaki
S
, Hida
S
, Ono
T
, Moriwake
T
, Yamauchi
S
, et al. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy
. J Clin Endocrinol Metab
. 1997
Jul
;82
(7
):2056
–61
.
[PubMed]
0021-972X30.
Yu
OH
, Richards
B
, Berger
C
, Josse
RG
, Leslie
WD
, Goltzman
D
, et al. The association between sclerostin and incident type 2 diabetes risk: a cohort study
. Clin Endocrinol (Oxf)
. 2017
Apr
;86
(4
):520
–5
.
[PubMed]
0300-066431.
Ugur-Altun
B
, Altun
A
, Gerenli
M
, Tugrul
A
. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity
. Diabetes Res Clin Pract
. 2005
Jun
;68
(3
):217
–22
.
[PubMed]
0168-822732.
Charatcharoenwitthaya
P
, Lindor
KD
, Angulo
P
. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease
. Dig Dis Sci
. 2012
Jul
;57
(7
):1925
–31
.
[PubMed]
0163-2116© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
